Larvol Delta - Marker-Therapeutics-Announces-FDA-Clearance-of-IND-for-MT601-the-sixantigen-targeted-T-Cell-Therapy-for-the-treatment-of-relapsedrefractory-NonHodgkin-Lymphoma

MT-601 - Marker Therap

https://www.globenewswire.com/news-release/2022/08/04/2492880/0/en/Marker-Therapeutics-Announces-FDA-Clearance-of-IND-for-MT-601-the-six-antigen-targeted-T-Cell-Therapy-for-the-treatment-of-relapsed-refractory-Non-Hodgkin-Lymphoma.html

Aug 4, 2022

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next